The University of Hull is a public university, founded in 1927, located in Kingston upon Hull, a city in the East Riding of Yorkshire, England. The main university campus is located in Hull and there is a smaller campus in Scarborough on the North Yorkshire coast. The main campus is home to the Hull York Medical School, a joint initiative with the University of York. Students are served by Hull University Union.The University's Brynmor Jones Library was the workplace of the poet Philip Larkin who served as its Head Librarian for over thirty years. The Philip Larkin Society organises activities in remembrance of Larkin including the Larkin 25 festival which was organised during 2010 in partnership with the University. The Library was also the workplace of former poet laureate Andrew Motion. Lord Wilberforce was chancellor of the University from 1978 until 1994. Robert Armstrong was the chancellor from 1994 to 2006. Virginia Bottomley was installed as the current chancellor in April 2006.Alumni of the University of Hull are especially prominent in the fields of politics, academia, journalism and drama. They include former MP and later Deputy Prime Minister Lord Prescott , former MP and Deputy Leader of the Labour Party Lord Hattersley , politician and author Chris Mullin, social scientist Lord Giddens , poet Roger McGough, journalist John McCarthy and film director, playwright and screenwriter Anthony Minghella. Wikipedia.
University of Hull | Date: 2017-07-26
The present invention relates to methods and systems for generating synthesised speech from detected speech articulator movement and to methods and systems for generating models for generating synthesised speech from detected articulator movement.
University of Hull | Date: 2017-07-26
A method of producing output indicative of the content of speech or mouthed speech from movement of speech articulators is described. The method comprises the following steps. Fixing a plurality of magnets respectively to a plurality of speech articulators of a human individual. Providing a plurality of signal magnetic field sensors located so as to sense a magnetic field intensity component produced by at least one of the magnets and a component produced by the Earths magnetic field. Providing at least three reference magnetic field sensors able to sense a magnetic field intensity produced at least partially by the Earths magnetic field. Obtaining, over the period of time, for each said signal magnetic field sensor signal, a respective correction value. Each correction value being indicative of the component that is produced by the Earths magnetic field and the magnetic field intensity sensed by the corresponding signal magnetic field sensor.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: BG-02-2015 | Award Amount: 5.59M | Year: 2016
CERES advances a cause-and-effect understanding of how future climate change will influence Europes most important fish and shellfish populations, their habitats, and the economic activities dependent on these species. CERES will involve and closely cooperate with industry and policy stakeholders to define policy, environment, social, technological, law and environmental climate change scenarios to be tested. This four-year project will: 1. Provide regionally relevant short-, medium- and long-term future, high resolution projections of key environmental variables for European marine and freshwater ecosystems; 2. Integrate the resulting knowledge on changes in productivity, biology and ecology of wild and cultured animals (including key indirect / food web interactions), and scale up to consequences for shellfish and fish populations, assemblages as well as their ecosystems and economic sectors; 3. Utilize innovative risk-assessment methodologies that encompass drivers of change, threats to fishery and aquaculture resources, expert knowledge, barriers to adaptation and likely consequences if mitigation measures are not put in place; 4. Anticipate responses and assist in the adaptation of aquatic food production industries to underlying biophysical changes, including developing new operating procedures, early warning methods, infrastructures, location choice, and markets; 5. Create short-, medium- and long-term projections tools for the industry fisheries as well as policy makers to more effectively promote blue growth of aquaculture and fisheries in different regions; 6. Consider market-level responses to changes (both positive and negative) in commodity availability as a result of climate change; 7. Formulate viable autonomous adaptation strategies within the industries and for policy to circumvent/prevent perceived risks or to access future opportunities; 8. Effectively communicate these findings and tools to potential end-users and relevant stakeholders.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: LCE-07-2016-2017 | Award Amount: 7.17M | Year: 2016
FIThydro addresses the decision support in commissioning and operating hydropower plants (HPP) by use of existing and innovative technologies. It concentrates on mitigation measures and strategies to develop cost-efficient environmental solutions and on strategies to avoid individual fish damage and enhancing population developments. Therefore HPPS all over Europe are involved as test sites. The facilities for upstream and downstream migration are evaluated, different bypass systems including their use as habitats and the influence of sediment on habitat. In addition existing tools and devices will be enhanced during the project and will be used in the experimental set-ups in the laboratories and at the test sites for e.g. detection of fish or prediction of behavior. This includes sensor fish, different solutions for migration as e.g. trash rack variations, different fish tracking systems, but also numerical models as habitat and population model or virtual fish swimming path model. Therefore a three-level-based workplan was created with preparatory desk work at the beginning to analyze shortcomings and potential in environment-friendly hydropower. Following the experimental tests will be conducted at the different test sites to demonstrate and evaluate the effects of the different options not covered by the desk-work. Thirdly, these results are fed into a risk based Decision Support System (DSS) which is developed for planning, commissioning and operating of HPPs. It is meant to enable operators to fulfill the requirements of cost-effective production and at the same time meet the environmental obligations and targets under European legislation and achieve a self-sustained fish population.
Agency: European Commission | Branch: H2020 | Program: MSCA-RISE | Phase: MSCA-RISE-2016 | Award Amount: 1.04M | Year: 2017
Lung cancer is the most common cancer worldwide. NSCLC alone make up about 75% of all lung cancers and most hospitals currently test all NSCLC patients for EGFR mutations (pharmacogenomics) for treatment decision (personalised medicine) i.e., patients with mutation(s) in EGFR gene should receive a EGFR-Tyrosine Kinase Inhibitor (TKI) drug (e.g. afitinib) treatment; while those that do not present mutations in such gene, should be treated with chemotherapy. Currently, the laboratories use PCR and Sanger sequencing technologies to perform the EGFR analysis from tumour biopsies - Fixed Paraffin Embedded (FFPE) samples. Still, some patients (e.g., 30% in UK) may never get histological confirmation because they are too sick to make a biopsy. Furthermore, the results obtained with current methods still present low quality, mainly due to poor quality/low yield of DNA extracted from FFPE samples. The FP7 LungCARD project (www.lungcard.eu) has developed and demonstrated a LungCARD system - an automatic system composed by microfluidic chip and chip analyser - that allows to capture circulating tumour cells (CTCs) from blood samples, amplify by multiplex PCR and detect EGFR mutations, including also a software for data analysis and report. Although this new blood test has proven to be faster, cost-effective and human error-free, the detection of somatic mutations in EGFR gene at frequencies lower than 20% is still a weak point. Therefore, the main projects goal is to benefit from this technology, through the development, improvement, integration and validation of the LungCARD system with NGS workflow and development of a software for automatic reporting clinical results. However, LungCARD project aims to go further, by putting together a global and unique network of multidisciplinary scientists for exchange of knowledge and research training focused on non-small cell lung cancer.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: ICT-01-2016 | Award Amount: 4.89M | Year: 2017
Cyber-Physical-Systems harbor the potential for vast economic and societal impact in all major application domains, however in case of failure this may lead to catastrophic results for industry and society. Thus, ensuring the dependability of such systems is the key to unlocking their full potential and enabling European industries to develop confidently business models that will nurture their societal uptake. The DEIS project addresses this challenges by developing technologies that form a science of dependable system integration. In the core of these technologies lies the concept of a Digital Dependability Identity (DDI) of a component or system. DDIs are composable and executable in the field facilitating (a) efficient synthesis of component and system dependability information over the supply chain and (b) effective evaluation of this information in-the-field for safe and secure composition of highly distributed and autonomous CPS. This concept shall be deployed and evaluated in four use cases: Automotive: Stand-alone system for intelligent physiological parameter monitoring Automotive: Advanced driver simulator for evaluation of automated driving functions Railway: Plug-and-play environment for heterogeneous railway systems Healthcare: Clinical decision support app for oncology professionals The DEIS project will impact the CPS market by providing new engineering methods and tools reducing significantly development time and cost of ownership, while supporting integration and interoperability of dependability information over the product lifecycle and over the supply chain. The development and application of the DDI approach on four use cases from three different application domains will illustrate the applicability of the DDI concept while increasing the competitiveness of the use case owners in their respective markets.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: FETOPEN-01-2016-2017 | Award Amount: 3.90M | Year: 2017
ONE-FLOW translates vertical hierarchy of chemical multistep synthesis with its complex machinery into self-organising horizontal hierarchy of a compartmentalized flow reactor system a biomimetic digital flow cascade machinery with just one reactor passage. To keep horizontal hierarchy manageable, orthogonality among the consecutive reactions needs to be increased. The winning point of nature is to have invented catalytic cascades. ONE-FLOW will uplift that by enabling the best bio- and chemocatalysts working hand in hand. 4 synthetic flow cascades (metabolic pathways) and 1 flow cascade driven by automated intelligence (signaling pathway) will produce 4 Top-list 2020 drugs. The Compartmentalized Smart Factory will develop organic, inorganic, and mechanical compartmentalization. The Green-Solvent Spaciant Factory will fluidically allow the use of interim reaction spaces (spaciants). The Systemic Operations Factory will aim at full orthogonality using data-base guided ultimate process harmonization. The Digital Machine-to-Machine Factory will alter the landscape of chemical synthesis by virtue of the Internet of Chemical Things. Automated machine-to-machine data transfer enables relegation of process monitoring to central computer systems under the oversight of chemists. The Fully Continuous Integrated Factory will develop a commercial platform technology under the auspices of sustainability-driven process-design evaluation, making amenable the new kind of processing to all chemists. ONE-FLOW has massive impact potential: i) 38 billion Euro production cost saving; ii) 300 million EUR cost saving per drug; iii) address diseases with 500 billion Euro medication costs; iv) increase market share of emerging high-tech SME players by 10% in 10 years; v) open new windows of opportunity (personalized medicine) with 200-500 million Euro per disease; and vi) achieve 40% female share on a senior scientist level (ONE-FLOW: 34% senior, 57% junior).
Agency: European Commission | Branch: H2020 | Program: MSCA-RISE | Phase: MSCA-RISE-2016 | Award Amount: 1.84M | Year: 2017
Cooling systems for Computing & Data Centres consume 30% to 40% of energy delivered into the centre spaces, while electricity use in CDCs represents 1.3% of the world total energy consumption. The traditional vapour compression cooling systems for CDCs are neither energy efficient nor environmentally friendly. Several alternative cooling systems, e.g., adsorption/absorption, ejector, and evaporative types, have certain level of energy saving potential but exhibit some inherent problems that have restricted their wide applications in CDCs. This RISE programme aims to form an international and inter-sectoral network of organisations working on a joint research and innovation programme dedicated to develop the design theory, computerised tool and technology prototypes for a novel CDC dew point cooling system. Such a system, comprising a few critical and highly innovative components (i.e., dew point air cooler, adsorbent sorption/regeneration cycle, micro-channels-loop-heat-pipe (MCLHP) based CDC heat recovery system, paraffin/expanded-graphite based heat storage/exchanger, and internet-based intelligent monitoring and control system), is expected to achieve 60% to 90% of electrical energy saving and have a comparable initial price to traditional CDC air conditioning systems, thus removing the above outstanding problems remaining with existing CDC cooling systems. Within the programme, the participants will exchange skills and knowledge that will allow them to progress towards the key target set for the CDC dew point cooling system, and strengthen collaborative research among different countries and sectors. The advances in the novel CDC dew point cooling system will have potential market opportunities for non-academic participants in the programme, and have significant benefits to European society and economy. The staff members who participate in the programme will develop new skills, be exposed to new research environments and have their career perspectives widened.
Aburima A.,University of Hull
Blood | Year: 2013
Cyclic adenosine monophosphate (cAMP)-dependent signaling modulates platelet shape change through unknown mechanisms. We examined the effects of cAMP signaling on platelet contractile machinery. Prostaglandin E1 (PGE1)-mediated inhibition of thrombin-stimulated shape change was accompanied by diminished phosphorylation of myosin light chain (MLC). Since thrombin stimulates phospho-MLC through RhoA/Rho-associated, coiled-coil containing protein kinase (ROCK)-dependent inhibition of MLC phosphatase (MLCP), we examined the effects of cAMP on this pathway. Thrombin stimulated the membrane localization of RhoA and the formation of a signaling complex of RhoA/ROCK2/myosin phosphatase-targeting subunit 1 (MYPT1). This resulted in ROCK-mediated phosphorylation of MYPT1 on threonine 853 (thr(853)), the disassociation of the catalytic subunit protein phosphatase 1δ (PP1δ) from MYPT1 and inhibition of basal MLCP activity. Treatment of platelets with PGE1 prevented thrombin-induced phospho-MYPT1-thr(853) in a protein kinase A (PKA)-dependent manner. Examination of the molecular mechanisms revealed that PGE1 induced the phosphorylation of RhoA on serine(188) through a pathway requiring cAMP and PKA. This event inhibited the membrane relocalization of RhoA, prevented the association of RhoA with ROCK2 and MYPT1, attenuated the dissociation of PP1δ from MYPT1, and thereby restored basal MLCP activity leading to a decrease in phospho-MLC. These data reveal a new mechanism by which the cAMP-PKA signaling pathway regulates platelet function.
Wraith K.S.,University of Hull
Blood | Year: 2013
Oxidized low-density lipoproteins (oxLDL) generated in the hyperlipidemic state may contribute to unregulated platelet activation during thrombosis. Although the ability of oxLDL to activate platelets is established, the underlying signaling mechanisms remain obscure. We show that oxLDL stimulate platelet activation through phosphorylation of the regulatory light chains of the contractile protein myosin IIa (MLC). oxLDL, but not native LDL, induced shape change, spreading, and phosphorylation of MLC (serine 19) through a pathway that was ablated under conditions that blocked CD36 ligation or inhibited Src kinases, suggesting a tyrosine kinase-dependent mechanism. Consistent with this, oxLDL induced tyrosine phosphorylation of a number of proteins including Syk and phospholipase C γ2. Inhibition of Syk, Ca(2+) mobilization, and MLC kinase (MLCK) only partially inhibited MLC phosphorylation, suggesting the presence of a second pathway. oxLDL activated RhoA and RhoA kinase (ROCK) to induce inhibitory phosphorylation of MLC phosphatase (MLCP). Moreover, inhibition of Src kinases prevented the activation of RhoA and ROCK, indicating that oxLDL regulates contractile signaling through a tyrosine kinase-dependent pathway that induces MLC phosphorylation through the dual activation of MLCK and inhibition of MLCP. These data reveal new signaling events downstream of CD36 that are critical in promoting platelet aggregation by oxLDL.